Observational Study of Denosumab (Prolia®) in Postmenopausal Women With

Clinical Trial Description

The decision to treat patients with denosumab was made independent of and before their enrolment in the study. No study drug was administered as part of the study. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05902078` - Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Phase 4
Completed	`NCT05087030` - Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT01544894` - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis	Phase 4
Completed	`NCT00381251` - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Phase 1
Completed	`NCT00377819` - Study of Transitioning From Alendronate to Denosumab	Phase 3
Completed	`NCT00239629` - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial	Phase 4
Completed	`NCT04026256` - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration	Phase 4
Terminated	`NCT00529373` - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)	Phase 3
Completed	`NCT00092014` - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)	Phase 3
Recruiting	`NCT06079476` - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.	Phase 4
Not yet recruiting	`NCT04719650` - Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid	Phase 4
Recruiting	`NCT02981732` - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome	N/A
Completed	`NCT01709110` - VERtebral Fracture Treatment Comparisons in Osteoporotic Women	Phase 4
Completed	`NCT01348243` - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT00541658` - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis	Phase 3
Completed	`NCT00395395` - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women	Phase 1
Completed	`NCT00247273` - A Study of Monthly Risedronate for Osteoporosis	Phase 3
Active, not recruiting	`NCT03720886` - G56W1 in Women With Postmenopausal Osteoporosis	Phase 1/Phase 2
Completed	`NCT04664959` - A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis	Phase 3
Not yet recruiting	`NCT04719481` - Pravastatin Reduces Acute Phase Response of Zoledronic Acid	Phase 4

NCT number	NCT01668589
Study type	Observational
Source	Amgen
Contact
Status	Completed
Phase	N/A
Start date	November 28, 2011
Completion date	August 31, 2015

Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms